BHC: Bausch Health Companies Inc. Stock

by  •  • Comments Off on BHC: Bausch Health Companies Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 1,624.00
Enterprise Value ($M) 22,943.00
Book Value ($M) -322.00
Book Value / Share -3.48
Price / Book -5.04
NCAV ($M) -20,929.00
NCAV / Share -57.74
Price / NCAV -0.08

Profitability (mra)
Return on Invested Capital (ROIC) -0.00
Return on Assets (ROA) -0.00
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio 0.97
Current Ratio 1.35

Balance Sheet (mrq) ($M)
Current Assets 5,732.00
Assets 26,421.00
Liabilities 26,661.00
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 9,625.00
Operating Income 1,976.00
Net Income -46.00
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 1,597.00
Cash from Investing -454.00
Cash from Financing -868.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
05-21 13D/A Paulson & Co. Inc. 7.10 2.32
05-21 13D/A Icahn Partners Master Fund LP 9.40
05-15 13G Nomura Holdings Inc 6.30 79.54
04-07 13D Meruelo Alex 9.99
08-19 13D/A Icahn Carl C

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-05-01 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT
2025-02-20 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SE
2024-10-31 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 OR ☐ TRANSITION REPORT PURSU
2024-08-01 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT T

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-06-02 131,905 1,033,093 12.77
2025-05-30 133,571 793,508 16.83
2025-05-29 193,993 775,960 25.00
2025-05-28 153,358 799,647 19.18

(click for more detail)

Similar Companies
ADCT – ADC Therapeutics SA ANRO – Alto Neuroscience, Inc.
ANVS – Annovis Bio, Inc. BHVN – Biohaven Ltd.
BMY – Bristol-Myers Squibb Company


Financial data and stock pages provided by
Fintel.io

Finpedia: Bausch Health